A Case of the Richardson Syndrome Variant of Progressive Supranuclear Palsy With Apathy and Depression: Clinical Evaluation and Symptomatic Treatment

David R. Spiegel, MD; Jamie A. Parkerson, MS; Perry B. Hammond, BA; Rachelle L. Gonzalez, BS; Joseph W. Bannister, BS

Prim Care Companion CNS Disord 2022;24(6):21cr03229

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

References (13)

Liscic RM, Srulijes K, Gröger A, et al. Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools. Acta Neurol Scand. 2013;127(5):362–370. PubMed CrossRef
Gerstenecker A. The neuropsychology (broadly conceived) of multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Arch Clin Neuropsychol. 2017;32(7):861–875. PubMed CrossRef
Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12(2):233–239. PubMed CrossRef
Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699. PubMed CrossRef
Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47(1):1–9. PubMed CrossRef
Höglinger GU, Respondek G, Stamelou M, et al; Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society Criteria. Mov Disord. 2017;32(6):853–864. PubMed CrossRef
Respondek G, Stamelou M, Kurz C, et al; Movement Disorder Society-endorsed PSP Study Group. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord. 2014;29(14):1758–1766. PubMed CrossRef
Golbe LI. Progressive supranuclear palsy. Semin Neurol. 2014;34(2):151–159. PubMed CrossRef
Rittman T, Coyle-Gilchrist IT, Rowe JB. Managing cognition in progressive supranuclear palsy. Neurodegener Dis Manag. 2016;6(6):499–508. PubMed CrossRef
Ghosh BC, Carpenter RH, Rowe JB. A longitudinal study of motor, oculomotor and cognitive function in progressive supranuclear palsy. PLoS One. 2013;8(9):e74486. PubMed CrossRef
Gerstenecker A, Duff K, Mast B, et al; ENGENE-PSP Study Group. Behavioral abnormalities in progressive supranuclear palsy. Psychiatry Res. 2013;210(3):1205–1210. PubMed CrossRef
VandeVrede L, Ljubenkov PA, Rojas JC, et al. Four-repeat tauopathies: current management and future treatments. Neurotherapeutics. 2020;17(4):1563–1581. PubMed CrossRef
McFarland NR, Hess CW. Recognizing atypical parkinsonisms: “red flags” and therapeutic approaches. Semin Neurol. 2017;37(2):215–227. PubMed CrossRef